Boston Scientific cuts annual forecast, shares rise on reset

FierceBiotechErasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death

FierceBiotechIncyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off Rinvoq

FierceBiotechAbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

FierceBiotechProtagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits

CellGlobal genetic interaction network of a human cell maps conserved principles and informs functional interpretation of gene co-essentiality profiles

CellStabilizing MARCH7 as a ferro-guardian against ferroptosis

BioPharma DiveBoehringer dual-acting obesity shot hits mark in Phase 3 trial

BioWorldRead BioWorld's AACR 2026 coverage

Endpoints NewsRocket's PRV goes for $180M; Oruka targets $500M offering

Endpoints NewsBeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

Endpoints NewsIncyte claims double Phase 3 win in vitiligo, will file for approval

BioPharma DiveFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results